Total cases and costs with and without a PCV13 program.
收藏NIAID Data Ecosystem2026-03-10 收录
数据链接：
官方服务：
资源简介：
Total cases and costs with and without a PCV13 program.
应用场景：
创建时间：
2018-07-25
相关数据集
Pneumococcal vaccination rates with 95%-confidence intervals within two years in patients with “high-risk” condition for pneumococcal disease.
Pneumococcal vaccination rates with 95%-confidence intervals within two years in patients with “high-risk” condition for pneumococcal disease.
NIAID Data Ecosystem80
Pneumococcal vaccination rates with 95%-confidence intervals within two years in patients with “high-risk” condition for pneumococcal disease.
Pneumococcal vaccination rates with 95%-confidence intervals within two years in patients with “high-risk” condition for pneumococcal disease.
Figshare2019-08-08 更新50
An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
In September 2023, 10-valent pneumococcal conjugate vaccine (PCV) was replaced by 15-valent PCV (PCV15) in Sweden’s pediatric national immunization program. Following European approval of 20-valent PC
NIAID Data Ecosystem30
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
A new 20-valent pneumococcal conjugate vaccine (PCV20) provides protection against 20 pneumococcal serotypes. The vaccine has the potential to decrease the impact of pneumococcal diseases in society a
NIAID Data Ecosystem50
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
Despite the current pneumococcal vaccination program in England for older adults and adults with underlying conditions, disease burden remains high. We evaluated cost-effectiveness of 20-valent pneumo
Taylor & Francis Group2023-03-30 更新30
